Active	Status	Sponsor type	Region	Phase	Filter
6 Active 0 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Yang, Kun-Yu
NCT06749899: QL1706 (IPD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.	Recruiting	3	580	RoW	QL1706, Gemcitabine, Cisplatin, Intensity-modulated radiotherapy	Sun Yat-sen University, Qilu Pharmaceutical Co., Ltd.	Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer	12/28	12/30
PLATINUM, NCT03984357: Nivolumab Combined With Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma	Active, not recruiting	2	152	RoW	PD-1 blocking antibody, PD-1 blockade, Gemcitabine, GEM, Cisplatin, DDP, Intensity-modulated radiotherapy, IMRT	Sun Yat-sen University, Bristol-Myers Squibb	Nasopharyngeal Carcinoma	04/24	03/26